Polymerized staphylococcal protein a for treatment of diseases
US6447777B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 28, 1997 |
| Grant date | Sep 10, 2002 |
| Priority date | — |
| Expiry date | Mar 28, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Polymers and polymer conjugates comprising crosslinked Staphylococcal protein A, or crosslinked protein A-superantigen, or crosslinked functional derivatives thereof ranging in size from 12kDa to 1O,OOOkDa are useful in the treatment of autoimmune diseases, such as rheumatoid arthritis and ITP as well as neoplastic diseases. Compositions and pharmaceutical composition comprising chemically crosslinked polymers of protein A alone or protein A and bacterial enterotoxins, optionally further complexed with immunoglobulins and complement components, are disclosed, as are methods for making and using these compositions in the treatment of diseases. Plasma perfusates of protein A immunadsorbent columns in clinical use are shown to act through the leaching of polymers of protein A and protein A-Staphylococcal enterotoxin B having a broad range of molecular masses. Methods of treating patients by monitoring column plasma perfusates for either of these chemical entities and appropriately adjusting doses of perfusate are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.